Welcome to Peptide Card of AntiTbPdb
This page displays user query in tabular form. |
fkcrrwqwrmkklg details |
Primary information | |
---|---|
ID | antitb_1171, |
Name | 24709266 |
N-Terminal modification | LFcin17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Protein Derived |
Strain | From bovine lactoferricin |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium strain 2447 smooth transparent variant (SmT) |
Cell Line | IC50 = 14.2 ± 1.5 |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Permeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells. |
Other activities | Cell envelope |
PMID | None |
Year of Publication | Antibacterial |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1172, |
Name | 24709266 |
N-Terminal modification | LFcin17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Protein Derived |
Strain | From bovine lactoferricin |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium strain 2447 smooth transparent variant (SmT) |
Cell Line | IC90 = 18.9 ± 4.0 |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Permeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells. |
Other activities | Cell envelope |
PMID | None |
Year of Publication | Antibacterial |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1173, |
Name | 24709266 |
N-Terminal modification | LFcin17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Protein Derived |
Strain | From bovine lactoferricin |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium strain 2-151 smooth transparent variant (SmT) |
Cell Line | IC50 = 8.0 ± 1.5 |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Permeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells. |
Other activities | Cell envelope |
PMID | None |
Year of Publication | Antibacterial |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1174, |
Name | 24709266 |
N-Terminal modification | LFcin17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Protein Derived |
Strain | From bovine lactoferricin |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium strain 2-151 smooth transparent variant (SmT) |
Cell Line | IC90 = 22.8 ± 9.1 |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Permeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells. |
Other activities | Cell envelope |
PMID | None |
Year of Publication | Antibacterial |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1175, |
Name | 24709266 |
N-Terminal modification | LFcin17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Protein Derived |
Strain | From bovine lactoferricin |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium strain 2-151 smooth doomed variant (SmD) |
Cell Line | IC50 = 12.4 ± 0.3 |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Permeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells. |
Other activities | Cell envelope |
PMID | None |
Year of Publication | Antibacterial |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1176, |
Name | 24709266 |
N-Terminal modification | LFcin17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Protein Derived |
Strain | From bovine lactoferricin |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium strain 2-151 smooth doomed variant (SmD) |
Cell Line | IC90 = 21.5 ± 4.0 |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Permeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells. |
Other activities | Cell envelope |
PMID | None |
Year of Publication | Antibacterial |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1177, |
Name | 24709266 |
N-Terminal modification | D-LFcin17-30 |
C-Terminal Modification | fkcrrwqwrmkklg |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | D |
Origin | Cationic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium strain 2447 smooth transparent variant (SmT) |
Cell Line | IC50 = 10.7 ± 0.9 |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Permeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells. |
Other activities | Cell envelope |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1178, |
Name | 24709266 |
N-Terminal modification | D-LFcin17-30 |
C-Terminal Modification | fkcrrwqwrmkklg |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | D |
Origin | Cationic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium strain 2447 smooth transparent variant (SmT) |
Cell Line | IC90 = 14.4 ± 1.9 |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Permeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells. |
Other activities | Cell envelope |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1545, |
Name | 25613372 |
N-Terminal modification | D-LFcin17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | 14.4 μg/ml |
Inhibition Concentration | in vitro |
Sequence | 2015 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | induce expression of IFN-γ |
Combination Therapy | Cause structural damage to mycobacteria |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1900, |
Name | 24709266 |
N-Terminal modification | Bovine lactoferricin 17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Derived from bovine lactoferricin protein |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium 2447 smT |
Cell Line | IC50 = 14.2 ± 1.5 μM |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | NA |
In vivo Model | Tratment with this concentration inhibit 50% bacterial growth |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | Lipid bilayer |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1901, |
Name | 24709266 |
N-Terminal modification | Bovine lactoferricin 17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Derived from bovine lactoferricin protein |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium 2447 smT |
Cell Line | IC90 = 18.9 ± 4.0 μM |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | NA |
In vivo Model | Tratment with this concentration inhibit 90% bacterial growth |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | Lipid bilayer |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1902, |
Name | 24709266 |
N-Terminal modification | Bovine lactoferricin 17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Derived from bovine lactoferricin protein |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium 2-151 smT |
Cell Line | IC50 = 8.0 ± 1.5 μM |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | NA |
In vivo Model | Tratment with this concentration inhibit 50% bacterial growth |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | Lipid bilayer |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1903, |
Name | 24709266 |
N-Terminal modification | Bovine lactoferricin 17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Derived from bovine lactoferricin protein |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium 2-151 smT |
Cell Line | IC90 = 22.8 ± 9.1 μM |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | NA |
In vivo Model | Tratment with this concentration inhibit 90% bacterial growth |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | Lipid bilayer |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1904, |
Name | 24709266 |
N-Terminal modification | Bovine lactoferricin 17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Derived from bovine lactoferricin protein |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium 2-151 smD |
Cell Line | IC50 = 12.4± 0.3 μM |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | NA |
In vivo Model | Tratment with this concentration inhibit 50% bacterial growth |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | Lipid bilayer |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1905, |
Name | 24709266 |
N-Terminal modification | Bovine lactoferricin 17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Derived from bovine lactoferricin protein |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium 2-151 smD |
Cell Line | IC90 = 21.5± 4.0 μM |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | NA |
In vivo Model | Tratment with this concentration inhibit 90% bacterial growth |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | Lipid bilayer |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1906, |
Name | 24709266 |
N-Terminal modification | Bovine lactoferricin 17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | D |
Origin | Cationic |
Species | Natural |
Strain | Derived from bovine lactoferricin protein |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium |
Cell Line | Mycobacterium avium 2447 smT |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | NA |
In vivo Model | Tratment with this concentration inhibit 50% bacterial growth |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | Lipid bilayer |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1907, |
Name | 24709266 |
N-Terminal modification | Bovine lactoferricin 17-30 |
C-Terminal Modification | FKCRRWQWRMKKLG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 14 |
Source | D |
Origin | Cationic |
Species | Natural |
Strain | Derived from bovine lactoferricin protein |
Inhibition Concentration | Mycobacterium avium |
In Vitro/ In vivo | Mycobacterium avium |
Cell Line | Mycobacterium avium 2447 smT |
Inhibition Concentration | In vitro |
Sequence | 2014 |
Cytotoxicity | NA |
In vivo Model | Tratment with this concentration inhibit 90% bacterial growth |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | Lipid bilayer |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |